You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|
|---|---|
| Published in |
Journal of Clinical Oncology, May 2008
|
| DOI | 10.1200/jco.2007.15.0375 |
| Pubmed ID | |
| Authors |
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara |
| Abstract |
Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 40% |
| Colombia | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 918 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 8 | <1% |
| United States | 3 | <1% |
| Brazil | 3 | <1% |
| United Kingdom | 3 | <1% |
| India | 2 | <1% |
| Spain | 2 | <1% |
| Canada | 2 | <1% |
| Palestine, State of | 1 | <1% |
| Ireland | 1 | <1% |
| Other | 7 | <1% |
| Unknown | 886 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 162 | 18% |
| Other | 141 | 15% |
| Student > Ph. D. Student | 117 | 13% |
| Student > Master | 78 | 8% |
| Student > Bachelor | 71 | 8% |
| Other | 203 | 22% |
| Unknown | 146 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 497 | 54% |
| Agricultural and Biological Sciences | 64 | 7% |
| Biochemistry, Genetics and Molecular Biology | 56 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 41 | 4% |
| Chemistry | 16 | 2% |
| Other | 72 | 8% |
| Unknown | 172 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#905,097
of 25,837,817 outputs
Outputs from Journal of Clinical Oncology
#2,154
of 22,229 outputs
Outputs of similar age
#1,886
of 101,354 outputs
Outputs of similar age from Journal of Clinical Oncology
#3
of 191 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,229 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 191 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.